ARTICLE | Clinical News
Tumor Targeted Superantigen: ACTI will start this quarter a U.K. Phase II study of TTS Tumor Targeted Superantigen antibody in 20 patients with pancreatic cance
February 11, 2002 8:00 AM UTC
Active Biotech AB(SSE:ACTI), Lund, Sweden Product: Tumor Targeted Superantigen (TTS) Business: Cancer Therapeutic category: Antibodies Target: 5T4 tumor cell antigen Description: Antibody against th...